Pharmaceuticals
Daewoong Pharmaceutical's Long-Acting Niclosamide Shows High Promise Against Upcoming COVID-19 'Twindemic'
SEOUL, South Korea, Oct. 27, 2020 /PRNewswire/ -- Daewoong Pharmaceutical, a South Korean pharmaceutical giant announced that its Covid-19 treatment candidate of sustained-release niclosamide (DWRX2003) also showed promising study results for a fight against the upcoming 'Twindemic' involving COV...
2020-10-27 21:00
1300
I-Mab to Present Preclinical Data of TJ210 at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
SHANGHAI and GAITHERSBURG, Md., Oct. 27, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the Company will present the latest preclinical dat...
2020-10-27 20:05
4676
Alterity commences enrolling Multiple System Atrophy patients in bioMUSE Study
MELBOURNE, Australia and SAN FRANCISCO, Oct. 26, 2020 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") today announced it has commenced enrolling patients with Multiple System Atrophy (MSA) in its bioMUSE Study inthe United States. BioMUSE is a natur...
2020-10-27 10:03
3681
GMAX Biopharm gives first does of anti-body drug treating PAH in phase 1B trial
HANGZHOU, China, Oct. 26, 2020 /PRNewswire/ -- Gmax Biopharm today announces that the first dose of GMA301 was given to the patient in its phase1B trial to investigate the drug efficacy to treat pulmonary arterial hypertension (PAH). GMA 301 is the first antibody drug for PAH treatment. In the ph...
2020-10-26 18:00
1503
111, Inc. Teams Up with Huluwa Pharmaceutical to Explore the New Domain of "Internet + pharmaceutical"
SHANGHAI, Oct. 15, 2020 /PRNewswire/ -- On September 24, 111, Inc. (NASDAQ: YI) (the "Company" or "111") and Hainan Huluwa Pharmaceutical Group Co., Ltd. (SH: 605199) ("Huluwa Pharmaceutical") signed a strategic partnership agreement in Shanghai. Mrs. LIU Jingping, Chairperson of Huluwa Pharmace...
2020-10-16 05:40
16515
111 to be the Omni-channel Drug Commercialization Partner of Xiangxu Pharmaceutical for Traditional Chinese Medicine
SHANGHAI, Oct. 15, 2020 /PRNewswire/ -- On September 24, 111, Inc. (the "Company" or "111") and Guangzhou Xiangxue Pharmaceutical Co., Ltd. ("Xiangxue Pharmaceutical") officially signed a strategic partnership agreement (the "Agreement") to deepen collaboration to further develop the "Internet + ...
2020-10-16 05:35
15023
Gannex Received U.S. IND Approval for Its NASH Drug Candidate ASC42，an FXR Agonist
SHANGHAI, Oct. 11, 2020 /PRNewswire/ -- Gannex Pharma Co., Ltd., a wholly owned company of Ascletis Pharma Inc. (HKEX: 1672) announces today that it received investigational new drug application (IND) approval from FDA for its drug candidate ASC42, to conduct clinical trials for non-alcoholic ste...
2020-10-12 08:30
7863
Foresee Pharmaceuticals Announces NDA for CAMCEVI(TM) 42MG Accepted for Review by the FDA
TAIPEI, Oct. 8, 2020 /PRNewswire/ -- Foresee Pharmaceuticals Co., Ltd. (6576.TWO) ("Foresee") announced today that the 505(b)(2) New Drug Application (NDA) for FP-001 LMIS 50mg, or CAMCEVI™ 42MG, a ready-to-use 6-month depot formulation of leuprolide mesylate, has been accepted for review by the ...
2020-10-09 06:39
2072
I-Mab Receives China CDE Approval to Initiate Phase 3 Clinical Trial of Eftansomatropin in Pediatric Patients with Growth Hormone Deficiency
SHANGHAI and GAITHERSBURG, Md., Sept. 30, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the China Center for Drug Evaluation (CDE) has app...
2020-09-30 20:00
11817
The 11th China (Taizhou) International Medical Expo ended successfully
NANJING, China, Sept. 30, 2020 /PRNewswire/ -- From September 19 to 21, the 11th China (Taizhou) International Medical Expo was held at the China Medical City Exhibition Center. With the theme of "Development Trends in the Medical and Health Industry under the Epidemic", the current medical expo h...
2020-09-30 19:52
1754
TaiGen Biotechnology Out-Licensed Taigexyn (Nemonoxacin) to Luminarie Canada for Canada, Australia and New Zealand
TAIPEI, Sept. 30, 2020 /PRNewswire/ -- TaiGen Biotechnology Company, Limited ("TaiGen")(Taiwan: 4157) today announced that they have signed an exclusive licensing agreement with Luminarie Canada Inc. ("Luminarie"), a leading Canadian pharmaceutical company, to develop and commercialize Taigexyn® ...
2020-09-30 15:51
1918
VolitionRx Limited Announces Virtual Capital Markets Day 2020
AUSTIN, Texas, Sept. 29, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases, today announced it will host a capital market...
2020-09-29 20:00
9761
GenScript ProBio Congratulates XLifeSc on FDA Allowance of IND Application for TCR-T Program
NANJING, China, Sept. 24, 2020 /PRNewswire/ -- On September 24, XiangXue Life Sciences (XLifeSc), a partner of GenScript ProBio, announces FDA allowance of its IND application for TCR-T program (TCRT-ESO-A2). GenScript ProBio extends congratulations on this. This program is China's first TCR-T...
2020-09-24 22:00
2078
Samsung Biologics signs strategic partnership with Kanaph Therapeutics to develop treatment for retinal diseases
INCHEON, South Korea, Sept. 23, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) and Kanaph Therapeutics have entered into a strategic partnership to develop KNP-301, a bi-specific Fc fusion protein intended to treat retinal diseases. According to Kanaph Therapeutics, KNP-301 is designed to ta...
2020-09-24 08:00
1556
ImmVira Announces US$10 million Strategic Series B Plus Financing with SIIC Capital
SHENZHEN and SHANGHAI, Sept.23, 2020 /PRNewswire/ -- ImmVira Group Company, a biotechnology company focused on the development of new generation oncolytic viruses as potential cancer therapeutics today announced signing ofUS$10 million Series B Plus strategic financing. This round of financing wi...
2020-09-24 00:09
2203
I-Mab Announces China NMPA Clearance for Phase 1 Clinical Trial of Lemzoparlimab in Relapsed or Refractory Advanced Lymphoma
SHANGHAI and GAITHERSBURG, Md., Sept. 21, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the Center for Drug Evaluation (CDE) of the China ...
2020-09-21 20:00
5974
PharmAbcine expands partnership with Samsung Biologics for PMC-403
DAEJEON, South Korea, Sept. 21, 2020 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks) entered into a strategic partnership with Samsung Biologics (KRX: 207940.KS) for the development and manufacturing of PMC-403 pipeline, the next generation therapeutic antibody candidate to treat neovascular ...
2020-09-21 20:00
1751
Preparation products of Yiling Pharma approved by FDA for launch in the US market
SHIJIAZHUANG, China, Sept. 19, 2020 /PRNewswire/ -- Yiling Pharmaceutical Co., Ltd. announced on Friday that it had received the approvals of the Abbreviated New Drug Applications (ANDA) about Lisinopril Tablets and Acyclovir Capsules, from United States Food and Drug Administration (hereinafter ...
2020-09-19 19:14
2777
MorphoSys and I-Mab Announce FDA Clearance of IND Application for MOR210/TJ210 in Patients with Advanced Cancer
PLANEGG/MUNICH, Germany and SHANGHAI, China, Sept. 17, 2020 /PRNewswire/ -- MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) and I-Mab (Nasdaq: IMAB) today jointly announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug applic...
2020-09-18 04:05
11076
Dr. Steven Yu Joins ChemPartner as Vice President of Regulated Bioanalysis
SHANGHAI, Sept. 17, 2020 /PRNewswire/ -- Shanghai ChemPartner announced today the appointment ofSteven Yu, Ph.D. as Vice President of Regulated Bioanalysis at the company headquarters inShanghai, China. Dr. Yu has more than 15 years of experience in drug development and extensive expertise in...
2020-09-17 23:01
2509
Week's Top Stories
Most Reposted
Cornerstone Robotics Raises over US$70 million Funding to Forge Accessibility in Robotic Surgery
[Picked up by 323 media titles]
2025-01-13 09:05
URBAN REVIVO Celebrates Lunar New Year with Unique Collaboration with Artist Mercedes Bellido
[Picked up by 293 media titles]
2025-01-13 10:44
Gen Z Travelers Drive Buy Now, Plan Later Travel Bookings by Over 20%: Fliggy's 2024 Buy Now Plan Later Travel Insight
[Picked up by 286 media titles]
2025-01-10 16:04RuggON Launches VIKING II: Transforming Fleet Management with Unmatched Technology and Flexibility
[Picked up by 285 media titles]
2025-01-14 21:00
VANTAGE FOUNDATION SUPPORTS GRAB INDONESIA IN EMPOWERING WOMEN DRIVER-PARTNER
[Picked up by 280 media titles]
2025-01-09 18:26
Most Read
Hyundai Motor Group Partners with NVIDIA to Accelerate Development of AI Solutions for Future Mobility
2025-01-10 01:00
20322
AIMA Unveils Game-Changing 2025 eBike Lineup at CES: Better Performance, More Freedom
2025-01-09 02:34
6480
RingConn Takes Center Stage at CES 2025 with Innovative Wearables: Gen 2 and Gen 2 Air
2025-01-11 01:00
5610
Boqii Announces ADS Ratio Change
2025-01-11 05:30
4945
Sino Land Included in Dow Jones Sustainability World Index
2025-01-10 22:01
4926
